Sec. 10.10.13.17. Testing — First-Tier  


Latest version.
  • A. The Department’s public health laboratory shall test, using first-tier tests, appropriately timed and collected blood-spot specimen of a newborn infant’s blood for the disorders listed in Regulation .12C of this chapter.

    B. Full-Term Healthy Newborn Infants.

    (1) If a newborn infant is born at term and is healthy, the Department’s public health laboratory shall conduct a:

    (a) First screening using first-tier tests to detect the disorders listed in Regulation .12C of this chapter on a blood-spot specimen collected when the full-term healthy newborn infant is between 24 and 48 hours old; and

    (b) Second screening using first-tier tests on a blood-spot specimen collected when the full-term healthy infant is between 10 and 14 days old.

    (2) If the first blood-spot specimen is collected when a full term healthy newborn infant is younger than 24 hours old, the Department’s public health laboratory shall conduct a:

    (a) Second screening using first-tier tests to detect the disorders listed in Regulation .12C of this chapter on a blood-spot specimen collected when the newborn infant is between 24 hours and 7 days old; and

    (b) Third screening using first-tier tests on a blood-spot specimen collected when the full-term healthy infant is between 1 and 4 weeks old.

    C. Premature or Ill Newborn Infant.

    (1) If a newborn infant who is born prematurely or expected to be ill for more than 14 days was younger than 24 hours old when the blood-spot specimen was collected for a first screening, the Department’s public health laboratory shall conduct a:

    (a) Second screening using first-tier tests to detect the disorders listed in Regulation .12C of this chapter when the newborn infant is between 24 hours and 3 days old; and

    (b) Third screening using first-tier tests when the newborn infant is between 7 days and 14 days old to screen for:

    (i) Amino acid disorders as specified in Regulation .12C(11)-(24) of this chapter;

    (ii) Acylcarnitine disorders as specified in Regulation .12C(25)-(52) of this chapter;

    (iii) Congenital hypothyroidism as specified in Regulation .12C(4) of this chapter; and

    (iv) Severe combined immunodeficiency, as specified in Regulation .12C(54) of this chapter.

    (2) If a newborn infant who is born prematurely or expected to be ill for more than 14 days was 24 hours old or older at the time the newborn infant’s blood-spot specimen was collected for a first screening, the Department’s public health laboratory shall perform a second screening to screen for:

    (a) Amino acid disorders as specified in Regulation .12C(11)-(24) of this chapter;

    (b) Acylcarnitine disorders as specified in Regulation .12C(25)-(52) of this chapter;

    (c) Congenital hypothyroidism as specified in Regulation .12C(4) of this chapter; and

    (d) Severe combined immunodeficiency, as specified in Regulation .12C(54) of this chapter.

    (3) If a newborn infant was transfused before the blood-spot specimen was collected for a first screening, the Department’s public health laboratory shall conduct, in addition to any other screenings specified in §B(1) and (2) of this regulation, a fourth screening using first-tier tests on a blood-spot specimen collected 4 months after a newborn infant’s last transfusion to screen for:

    (a) Hemoglobin as specified in Regulation .12C(7)-(10) of this chapter;

    (b) Biotinidase as specified in Regulation .12C(1) of this chapter; and

    (c) Galactose-1-P-uridyl-1-transferase as specified in Regulation .12C(3) of this chapter.